Pharmacogenomics in acute coronary syndrome

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 3, 2008, Pages 363-376

  Remmler, Cornelia ^a   Cascorbi, Ingolf ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Coronary artery disease; Genetic polymorphism; Glycoprotein; Leukocyte adhesion; Myocardial infarction; Thrombocyte aggregation

Indexed keywords

ABCIXIMAB; ACENOCOUMAROL; APOLIPOPROTEIN; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR; BUCINDOLOL; CARVEDILOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPTIFIBATIDE; FIBRINOGEN; FLUINDOSTATIN; GEMFIBROZIL; GLYCOPROTEIN; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; METOPROLOL; ORBOFIBAN; PHENPROCOUMON; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; SIMVASTATIN; TIROFIBAN; UNINDEXED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; BLOOD CLOTTING; CLINICAL TRIAL; DISEASE MARKER; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG UPTAKE; FIBRINOLYSIS; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HEART FAILURE; HEART INFARCTION; HETEROZYGOTE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID METABOLISM; LIPID TRANSPORT; MEDICAL DECISION MAKING; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PROTEIN DETERMINATION; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENESIS; THROMBOSIS; GENETICS; PHARMACOGENETICS; RISK;

ACUTE CORONARY SYNDROME; BLOOD COAGULATION; FIBRINOLYSIS; HUMANS; LIPID METABOLISM; LIPOPROTEIN LIPASE; NITRIC OXIDE SYNTHASE TYPE III; PHARMACOGENETICS; PLATELET AGGREGATION; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM; RISK;

EID: 39049118987     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.3.363     Document Type: Review

References (124)

1. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007;357:443-53
2. Moshfegh K, Wuillemin WA. Redondo M, et al. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infitrction: a case-control study. Lancet 1999;353:351-4
3. Casorelli I. De Stefano V, Leone AM, et al. The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population. Br J Haematol 2001;114:150-4
4. Santoso S, Kunicki TJ, Kroll H, et al. Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 1999;93:2449-53
5. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003;107:1117-22
6. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. 807 C/T Polymorphison of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. Blood Coagul Fibrinolysis 2004;15:427-33
7. Corral J, Gonzalez-Conejero R, Lozano ML, et al. New alleles of the platelet glycoprotein Ibalpha gene. Br J Haematol 1998;103:997-1003
8. Simsek S, Bleeker PM, van der Schoot CE, dem Borne AE. Association of a variable number of tandem repeats (VNTR) in glycoprotein Ib alpha and HPA-2 alloantigens. Thromb Haemost 1994;72:757-61
9. Ishida F, Ito T, Takei M, et al. Genetic linkage of Kozak sequence polymorphism of the platelet glycoprotein Ib alpha with human platelet antigen-2 and variable number of tandem repeats polymorphism, and its relationship with coronary artery disease. Br J Haematol 2000;111:1247-9
10. Mikkelsson J, Perola M, Penttila. A. Karhunen PJ. Platelet glycoprotein Ibalpha HPA-2 Med/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death. Circulation 2001;104:876-80
11. Gonzalez-Conejero R, Lozano ML, Rivera J, et al. Polymorphisms of platelet membrane glycoprotein Ib associated with arterial thrombotic disease. Blood 1998;92:2771-6
12. Mercier B, Munier S, Bertault V, et al. Myocardial infarction: absence of association with VNTR polymorphism of GP Ibalpha. Thromb Haemost 2000;84:921-2
13. Meisel C, Afshar-Kharghan V, Cascorbi I, et al. Role of Kozak sequence polymorphism of platelet glycoprotein Ibalpha as a risk factor for coronary artery disease and catheter interventions. J Am Coll Cardiol 2001;38:1023-7
14. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000;102:149-56
15. Kenny D, Muckian C. Fitzgerald DJ, et al. Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients. J Thromb Thrombolysis 2002;13:13-9
16. Plow EF, D'Souza SE, Ginsberg MH. Ligand binding to GPIIb-IIIa- a status report. Semin Thromb Hemost 1992;18:324-32
17. Reiner AP, Siscovick DS, Rosendaal FR. Platelet glycoprotein gene polymorphisms and risk of thrombosis: facts and fancies. Rev Clin Exp Hematol 2001;5:262-87
18. Park S, Park HY, Park C, et al. Association of the gene polymorphisms of platelet glycoprotein Ia and IIb/IIIa with myocardial infarction and extent of coronary artery disease in the Korean population. Yonsei Med J 2004;45:428-34
19. Bottiger C. Kastrati A. Koch W, et al. HPA-1 and HPA-3 polymorphisms of the platelet fibrinogen receptor and coronary artery disease and myocardial infarction. Thromb Haemost 2000;83:559-62
20. Gardemann A, Humme J, Stricker J, et al. Association of the platelet glycoprotein IIIa PlA1/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients. Thromb Haemost 1998;80:214-7
21. Tobin MD, Braund PS, Burton PR, et al. Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. Eur Heart J 2004;25:459-67
22. Laule M, Cascorbi I, Stangl V, et al. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study. Lancet 1999;353:708-12
23. O'Connor FF, Shields DC, Fitzgerald A, et al. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 2001;98:3256-60
24. Aalto-Setala K Karhunen PJ, Mikkelsson J, Niemela K. The effect of glycoprotein IIIa PIA I/A2 polymorphisin on the PFA-100 response to GP IIb IIa receptor inhibitors-the importance of anticoagulants used. J Thromb Thrombolysis 2005;20:57-63
25. Bauduer F, Lacombe D. Factor V Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T, and population genetics. Mol Genet Metab 2005;86:91-9
26. Endler G, Mannhalter C. Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. Clin Chim Acta 2003;330:31-55
27. Burzotta F, Leone AM, Paciaroni K, et al. G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome. Haematologica 2004;89:1134-8
28. Doggen CJ, Cats VM, Bertina, RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998;97:103741
29. Green F, Kelleher C, Wilkes H, et al. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991;11:540-6
30. Lane A, Green F, Scarabin PY, et al. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis 1996;119:119-27
31. Mrozikiewicz PM, Cascorbi I, Ziemer S, et al. Reduced procedural risk for coronary catheter interventions in carriers of the coagulation factor VII-Gln353 gene. J Am Coll Cardiol 2000;36:1520-5
32. Kanaji T, Okamura T, Osaki K, et al. A common genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998;91:2010-4
33. Santamaria A. Martinez-Rubio A. Mateo J, et al. Homozygosity of the T allele of the 46 C≥T polymorphism in the F12 gene is a risk factor for acute coronary artery disease in the Spanish population. Haematologica 2004;89:878-9
34. Nahrendorf M, Hu K, Frantz S, et al. Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction. Circulation 2006;113:1196-202
35. Hancer VS, Diz-Kucukkaya R, Bilge AY, et al. The association between factor XIII Val34Leu, polymorphism and early myocardial infarction. Circ J 2006;70:239-42
36. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93
37. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007;7:99-111
38. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin, dose requirements: proposal for a new dosing regimen. Blood 2005;106:2329-33
39. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2007
40. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005;44:1227-46
41. Gils A. Declerck PJ. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb Haemost 2004;91:425-37
42. Dawson SJ, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-I (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993;268:10739-45
43. Eriksson P, Kallin B, van't Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995;92:1851-5
44. Pegoraro RJ, Ranjith N. Plasminogen activator inhibitor type 1 (PAI-1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in young Asian Indians with acute myocardial infarction. Cardiovasc J S Afr 2005;16:266-70
45. Gardemann A. Lohre J, Katz N, et al. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost 1999;82:1121-6
46. Mannila MN, Eriksson P, Lundman P, et al. Contribution of haplotypes across the fibrinogen gene cluster to variation in risk of myocardial infarction. Thromb Haemost 2005;93:570-7
47. de Maat MP, Kastelein JJ, Jukems JW, et al. -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction partern of fibrinogen. REGRESS group. Arterioscler Thromb Vasc Biol 1998;18:265-71
48. Pegoraro RJ, Ranjith N, Rom L. Coagulation gene polymorphisms as risk factors for myocardial infarction in young Indian Asians. Cardiovasc J S Afir 2005;16:152-7
49. Maitland-van der Zee AH, Klungel OH, Snicker BH, et al. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002;163:213-22
50. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism, in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992,359:641-4
51. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism, in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6
52. Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism, and the risk of ischemic heart disease. N Engl J Mcd 1995;332:706-11
53. Holmer SR, Bickeboller H, Hengstenherg C, et al. Angiotensin converting enzyme gene polymorphism and myocardial infarction a large association and linkage study. Int J Biochem Cell Biol 2003;35:955-62
54. Fernandez-Arcas N, Dieguez-Lucena, JL Munoz-Moran E, et al. Both alleles of the M235T polymorphism of the angiotensinogen gene can be a risk factor for myocardial infarction. Clin Genet 2001;60:52-7
55. Goldenberg I, Moss AJ, Ryan D, et al. Polymorphism in the angiotensinogen gene. hypertension, and ethnic differences in the risk of recurrent coronary events. Hypertension 2006;48:693-9
56. Stangl K, Cascorbi I, Stangl V, et al. A1 166C polymorphism of the angiotensin II type 1 receptor gene and risk of adverse events after coronary catheter interventions. Am Heart J 2000;140:170-5
57. Paid S, Steeds R, Channer K, Samani NJ. Analysis of promoter region polymorphism in the aldosterone synthase gene (CYP11B2) as a risk factor for myocardial infarction. Am J Hypertens 2000;13:134-9
58. Bis JC, Smith NL, Psaty BM, et al. Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. Am J Hypertens 2003;16:1011-7
59. Schelleman H, Klungel OH. Witteman JC, et al. Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. Eur J Hum Genet 2007;15:478-84
60. Wang XL, Wang J. Endothelial nitric oxide synthase gene sequence variations and vascular disease. Mol Genet Metab 2000;70:241-51
61. Yoshimura M, Yasue H, Nakayama M, et al. Genetic risk factors for coronary artery spasm: significance of endothelial nitric oxide synthase gene T-786≥C and missense Glu298Asp variants. J Investig Med 2000;48:367-74
62. Ichihara S, Yamada Y, Fujimara T, et al. Association of a polymorphism of the endothelial constitutive nitric oxide synthase gene with myocardial infarction in the Japanese population. Am J Cardiol 1998;81:83-6
63. Wang XL, Sim AS, Badenhop RF, et al. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 1996;2:41-5
64. Gardemann A, Lohre J, Cayci S, et al. The T allele of the missense Glu(298)Asp endothelial nitric oxide syntbase gene polymorphism is associated with coronary heart disease in younger individuals with high atherosclerotic risk profile. Atherosclerosis 2002;160:167-75
65. Park KW, You KH, Oh S, et al. Association of endothdial constitutive nitric oxide synthase gene polymorphism with acute coronary syndrome in Koreans. Heart 2004;90:282-5
66. Antoniades C, Tousoulis D, Vasiliadou C. et al. Genetic polymorphism on endothelial nitric oxide synthase affects endothelial activation and inflammatory response during the acute phase of myocardial infarction. J Am Coll Cardiol 2005;46:1101-9
67. Tesauro M, Thompson WC, Rogliani R et al. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 2000;97:2832-5
68. Grossmann M, Dobrev D, Siffert W, Kirch W. Heterogeneity in hand veins responses to acetylcholine is not associated with polymorphiams in the G-protein beta3-subunit (C825T) and endothelial nitric oxide synthase (G894T) genes but with serum low density lipoprotein cholesterol. Pharmacogenetics 2001;11:307-16
69. Guzik TJ, Black E, West NE, et al. Relationship between the G894T polymorphism (Glu298Asp variant) in endothelial nitric oxide synthase and nitric oxide-mediated endothelial function in human atherosclerosis. Am J Med Genet 2001;100:130-7
70. Naber CK, Baumgart D, Altmann C, et al. eNOS 894T allele and coronary blood flow at rest and during adenosine-induced hyperemia. Am J Physiol Heart Circ Physiol 2001;281:H1908-12
71. Stangl K, Cascorbi I, Laule M, et al. High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. Pharmacogenetics 2000;10:133-40
72. Laule M, Meisel C, Prauka I, et al. Interaction of CA repeat polymorphism of the endothelial nitric oxide synthase and hyperhomocysteinemia in acute coronary syndromes: evidence of gender-specific differences. J Mol Med 2003;81:305-9
73. Wallerath T, Godecke A. Molojavyi A. et al. Dexamethasone lacks effect on blood pressure in mice with a disrupted endothelial NO synthase gene. Nitric Oxide 2004;10:36-41
74. van't Hooft FM, Jormsjo S, Lundahl B, et al. A functional polymorphism in the apolipoprotein B promoter thar influences the level of plasma low density lipoprotein. J Lipid Res 1999;40:1686-94
75. Baum L, Ng HK, Wong KS, et al. Associations of apolipoprotein E exon 4 and lipoprotein lipase S447X polymorphisms with acute ischemic stroke and myocardial infarction. Clin Chem Lab Med 2006;44:274-81
76. Keavney B, Palmer A. Parish S, et al. Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations, and coronary disease risk. Int J Epidemiol 2004;33:1002-13
77. Zee RY, Cook NR, Cheng S, et al. Multi-locus candidate gene polymorphisms and risk of myocardial infarction: a population-based, prospective genetic analysis. J Thromb Haemost 2006;4:341-8
78. Shioji K, Mannami T, Kokubo Y, et al. An association analysis between ApoA1 polymorphisms and the high-density lipoprotein (HDL) cholesterol level and myocardial infarction (MI) in Japanese. J Hum Genet 2004;49:433-9
79. Ruiz-Narvaez EA, Yang Y, Nakanishi Y, et al. APOC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica. J Lipid Res 2005;46:2605-13
80. Holmer SR, Hengstenberg C, Kraft HG, et al. Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction. Circulation 2003;107:696-701
81. de Padua MA, Annicchino-Bizzacchi J, Favarato D, et al. Angiotensin-converting enzyme and apolipoprotein B polymorphisms in coronary artery disease. Am J Cardiol 2000;85:1089-93
82. Liu S, Song Y. Hu FB, et al. A prospective study of the APOA1 XmnI and APOC3 SstI polymorphisms in the APOA1/C3/A4 gene cluster and risk of incident myocardial infarction in men. Atherosclerosis 2004;177:119-26
83. Kajinami K, Takekoshi N. Brousseau ME, Schaefer EJ. Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 2004;177:219-34
84. Takane H, Miyara M, Burioka N, et al. Pharmacogenetic determinants of variability in tipid-lowering response to pravastatin therapy. J Hum Genet 2006;51:822-6
85. Peacock RE, Hamsten A. Nilsson-Ehle P, Humphries SE. Associations between lipoprotein lipase gene polymorphisms and plasma correlations of lipids, lipoproteins and lipase activities in young myocardial infarction survivors and age-matched healthy individuals from Sweden. Atherosclerosis 1992;97:171-85
86. Brousseau ME, Goldkamp AL, Collins D, et al. Polymorphisms in the gene encoding lipoprotein lipase in men with low HDL-C and coronary heart disease: the Veterans Affairs HDL Intervention Trial. J Lipid Res 2004;45:1885-91
87. Baroni MG, Berni A, Romeo S, et al. Genetic study of common variants at the Apo E, Apo AI, Apo CIII, Apo B, lipoprorein lipase (LPL) and hepatic lipase (LIPC) genes and coronary artery disease (CAD): variation in LIPC gene associates with clinical outcomes in patients with established CAD. BMC Med Genet 2003;4
88. Fiegenbaum M, da Silveira FR, Van der Sand CR, et al. Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects. Clin Chim Acta 2005;362:182-8
89. Tatsuguchi M, Furutani M, Hinagata J, et al. Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. Biochem Biophys Res Commun 2003;303:247-50
90. Mango R, Clementi F. Borgiani P, et al. Association of single nucleotide polymorphisms in the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction. J Med Genet 2003;40:933-6
91. Trabetti E, Biscuola M, Carallari U, et al. On the association of the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction or coronary artery disease. Eur J Hum Genet 2006;14:127-30
92. Mango R, Biocca S, del Vecchio F, et al. In vivo and in vitro studies support that a new splicing isoform of OLR1 gene is protective against acute myocardial infarction. Circ Res 2005;97:152-8
93. Puccetti L, Pasqui AL, Bruni F, et al. Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment. Int J Cardiol 2006
94. Eiriksdottir G, Bolla MK, Thorsson B, et al. The -629C>A polymorphism, in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men. Atherosclerosis 2001;159:187-92
95. Borggreve SE, Hillege HL, Wolffenbuttel BH, et al. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 2006;91:3382-8
96. Winkelmann BR, Hoffmann MM, Nauck M, et al. Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy. Pharmacogenomics J 2003;3:284-96
97. Mayer B, Erdmann J, Schunkert H. Genetics and heritability of coronary artery disease and myocardial infarction. Clin Res Cardiol 2007;96:1-7
98. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rostivastatin. Clin Pharmacol Ther 2007
99. Mwinyi J, Johne A. Bauer S, et al. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004;75:415-21
100. Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisins and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004;14:429-40
101. Kirchheiner J, Kudlicz D, Meisel C, et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 2003;74:186-94
102. Maitland-van der Zee AH, Boerwinkle E. Pharmacogenctics of response to statins: where do we stand? Curr Atheroscler Rep 2005;7:204-8
103. Mangravite LM, Thorn CF. Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J 2006;6:360-74
104. Giessmann T, Modess C, Hecker U, et al. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther 2004;75:213-22
105. Rau T, Heide R, Bergmann K, et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002;12:465-72
106. Ismail R, Teh LK. The relevance of CYP2D6 generic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther 2006;31:99-109
107. Liu J, Liu ZQ, Tan ZR, et al. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 2003;74:372-9
108. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac Function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 2006;103:11288-93
109. Terra SG, Hamilton KK, Pauly DF, et al. Betal-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics 2005;15:227-34
110. Lebmeyer MT, Gong Y, Terra SG. et al. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics 2007;17:277-82
111. Lanfear DE, Jones PG, Marsh S, et al. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA 2005;294:1526-33
112. Topol EJ, McCarthy J, Gabriel S, et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 2001;104:2641-4
113. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial irfirction from polymorphisms in candidate genes. N Engl J Med 2002;347:1916-23
114. Shiffman D, Etlis SG, Rowland CM, et al. Identification of four gene variants associated with myocardial infarction. Am J Hum Genet 2005;77:596-605
115. Ranjith N, Pegoraro RJ, Rom L. et al. Lp(a) and apoE polymorphisms in young South African Indians with myocardial infarction. Cardiovasc J S Afr 2004;15:111-7
116. Cuisset T, Frere C, Quilici J. et al. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thromb Res 2007
117. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108:2244-7
118. Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005;106:135-40
119. Chasman DI, Posada D. Subrahmanyan L, et al. Pharmacogmetic study of statin therapy and cholesterol reduction. JAMA 2004;291:2821-7
120. Antonicelli R, Olivieri F, Bonafe M, et al. The interleukin-6 -174 G>C promoter polymorphism is associated with a higher risk of death after an acute coronary syndrome in male elderly patients. Int J Cardiol 2005;103:266-71
121. Maitland-van der Zee AH, Boerwinkle F, Arnett DK, et al. Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Am Heart J 2007;153:54-8
122. Beitelshees AL, Zineh I, Yarandi HN, et al. Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics. Pharmacogenomics J 2006;6:174-8
123. Sciarrone MT, Stella P, Barlassina C, et al. ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 2003;41:398-403
124. Klein TE, Chang JT, Cho MK et al. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J 2001;1:167-70. Available from: www.pharmgkb.org